

Resource Summary Report

Generated by [NIF](#) on Jul 29, 2026

IgG

RRID:AB_10611712

Type: Antibody

Proper Citation

BD Biosciences Cat# 561298, RRID:AB_10611712

Antibody Information

URL: http://antibodyregistry.org/AB_10611712

Proper Citation: BD Biosciences Cat# 561298, RRID:AB_10611712

Target Antigen: IgG

Host Organism: mouse

Clonality: monoclonal

Comments: Flow cytometry

Antibody Name: IgG

Description: This monoclonal targets IgG

Target Organism: human

Antibody ID: AB_10611712

Vendor: BD Biosciences

Catalog Number: 561298

Record Creation Time: 20250820T063358+0000

Record Last Update: 20250821T002603+0000

Ratings and Alerts

No rating or validation information has been found for IgG.

No alerts have been found for IgG.

Data and Source Information

Source: [Antibody Registry](#)

Usage and Citation Metrics

We found 13 mentions in open access literature.

Listed below are recent publications. The full list is available at [NIF](#) .

Kardava L, et al. (2025) Phenotypic heterogeneity defines B cell responses to repeated SARS-CoV-2 exposures through vaccination and infection. *Cell reports*, 44(4), 115557.

Ma KM, et al. (2025) HIV broadly neutralizing antibody precursors to the Apex epitope induced in nonhuman primates. *Science immunology*, 10(110), eadt6660.

Pelletier AN, et al. (2024) A pre-vaccination immune metabolic interplay determines the protective antibody response to a dengue virus vaccine. *Cell reports*, 43(7), 114370.

Matveev VA, et al. (2023) Immunogenicity of COVID-19 vaccines and their effect on HIV reservoir in older people with HIV. *iScience*, 26(10), 107915.

Mantus G, et al. (2022) Pre-existing SARS-CoV-2 immunity influences potency, breadth, and durability of the humoral response to SARS-CoV-2 vaccination. *Cell reports. Medicine*, 3(4), 100603.

Buckner CM, et al. (2022) Interval between prior SARS-CoV-2 infection and booster vaccination impacts magnitude and quality of antibody and B cell responses. *Cell*, 185(23), 4333.

Yu B, et al. (2022) Engineered cell entry links receptor biology with single-cell genomics. *Cell*, 185(26), 4904.

Seow J, et al. (2022) ChAdOx1 nCoV-19 vaccine elicits monoclonal antibodies with cross-neutralizing activity against SARS-CoV-2 viral variants. *Cell reports*, 39(5), 110757.

Yu B, et al. (2021) B cell-specific XIST complex enforces X-inactivation and restrains atypical B cells. *Cell*, 184(7), 1790.

Brouwer PJM, et al. (2021) Two-component spike nanoparticle vaccine protects macaques from SARS-CoV-2 infection. *Cell*, 184(5), 1188.

Graham C, et al. (2021) Neutralization potency of monoclonal antibodies recognizing dominant and subdominant epitopes on SARS-CoV-2 Spike is impacted by the B.1.1.7 variant. *Immunity*, 54(6), 1276.

Cirelli KM, et al. (2019) Slow Delivery Immunization Enhances HIV Neutralizing Antibody and Germinal Center Responses via Modulation of Immunodominance. *Cell*, 177(5), 1153.

Ahmed R, et al. (2019) A Public BCR Present in a Unique Dual-Receptor-Expressing Lymphocyte from Type 1 Diabetes Patients Encodes a Potent T Cell Autoantigen. *Cell*, 177(6), 1583.